MedTrace Logo

Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

NCT01228370 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2012-10-05

No results posted yet for this study

Summary

Because the bladder neck and proximal urethra contain abundant α1-adrenergic receptors, α-blockers or α1-blockers are well-known to reduce bladder neck obstruction in patients with or without neurogenic bladder.

α1-blockers seem to have a potential to reduce bladder outlet resistance during voiding in patients with neurogenic bladder.

Based on these turnouts, we designed this clinical study to evaluate the clinical effect and safety of silodosin on voiding dysfunction associated with neurogenic bladder.

Conditions

  • Neurogenic Bladder
  • Voiding Dysfunction

Interventions

DRUG

silodosin

silodosin 8mg once a day for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Duk-Yoon Kim · Daegu Catholic University Medical Center

  • Chul-Hee Park · Keimyung Univ. Dongsan Medical Center

  • Hee-Chang Jung · Yeungnam Univ. Medical Center

  • Kyung-Hyun Moon · Ulsan Univ. Hospital

  • Tae-Hee Oh · Samsung Changwon Hospital

  • Jae-Soo Kim · Daegu Fatima Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228370 on ClinicalTrials.gov